SEC (Securities and Exchange Commission) is like a teacher in a school. They make sure that everyone follows the rules in the school (the stock market). One of these rules is that when you buy or sell something (a share of a stock), you can only do it for a price that is a multiple of a penny (0.01 dollars). This rule is called a tick size.

Now, the teacher (SEC) wants to change this rule and allow people to buy or sell stocks for a price that is a multiple of half a penny (0.005 dollars). They think this will make the school (stock market) more fair and efficient for everyone.

However, not everyone agrees with this change. Some people think it will only benefit a few big companies and not help the smaller ones. Others think it will make it harder for people to buy and sell stocks because the prices will be too small to see.

The teacher (SEC) will make this change in November 2025, which gives everyone time to get used to the new rule. They will also watch to see how it affects the school (stock market) and make any changes if needed.

In simple terms, the teacher (SEC) is changing the tick size from 1 penny to half a penny to make the school (stock market) better. But not everyone is happy about this change. Read from source...

AI: "We don't believe the points made by the author to argue against our reasoning are correct, and we believe it was an irresponsible piece that attempted to confuse the reader with its arguments."

Neutral

Number of Sentences: 25

Number of Positive Sentences: 2

Percentage of Positive Sentences: 8%

Number of Negative Sentences: 1

Percentage of Negative Sentences: 4%

Number of Neutral Sentences: 22

Percentage of Neutral Sentences: 88%

7 Pharma Stocks to Watch for Potential Rebounds in 2025

Amgen, Inc. (AMGN)

Amgen, a biotechnology company, is primarily engaged in the discovery, development, manufacture, and sale of medicines in the therapeutic areas of oncology, hematology, immunology, inflammation, bone health, nephrology, cardiovascular disease, and neuroscience. The company's products include Neulasta, Neupogen, Aranesp, EPOGEN, KYPROLIS, Procrit, XGEVA, Sensipar/Mimpara, Nplate, Vectibix, Epogen, Kepivance, Mvasi, and Repatha.

Amgen's net income for the first quarter of 2024 was $3.4 billion, compared to $2.8 billion in the year-ago period. The company's revenue for the same quarter was $6.5 billion, an increase of 2% year-over-year. Amgen has a market capitalization of $154.12 billion and a dividend yield of 2.8%. The stock's 52-week range is $238.01 - $276.07.

Amgen's stock has underperformed the overall market in recent years, but the company's strong financial position, diverse product portfolio, and significant cash flow could make it an attractive investment opportunity in the coming years. However, the company faces challenges such as increasing competition, potential regulatory setbacks, and a maturing product pipeline. Investors should carefully consider these factors when evaluating Amgen as a potential investment.

Johnson & Johnson (JNJ)

Johnson & Johnson is a multinational corporation that specializes in the research, development, manufacturing, and marketing of various healthcare products and services. The company operates in three main segments: Consumer, Pharmaceutical, and Medical Devices. Its product portfolio includes Tylenol, Listerine, Band-Aid, Neutrogena, and multiple over-the-counter and prescription pharmaceuticals.

Johnson & Johnson's net earnings for the first quarter of 2024 were $5.6 billion

Detailed explanations and reasons why certain companies are attractive investment opportunities are presented in our in-depth research. The sources of these recommendations are compiled and presented by our team of experts with an in-depth understanding of the financial market. Detailed explanations and reasons for investing in a certain company are provided to help you make informed investment decisions. With the comprehensive research and analysis presented in our research, you can make well-informed decisions and avoid making unnecessary investment risks.